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Snail promotes ovarian cancer progression by
recruiting myeloid-derived suppressor cells via
CXCR2 ligand upregulation
Mana Taki1, Kaoru Abiko1, Tsukasa Baba1, Junzo Hamanishi1, Ken Yamaguchi1, Ryusuke Murakami1,
Koji Yamanoi1, Naoki Horikawa1, Yuko Hosoe1, Eijiro Nakamura2, Aiko Sugiyama2, Masaki Mandai1,
Ikuo Konishi1 & Noriomi Matsumura1
Snail is a major transcriptional factor that induces epithelial-mesenchymal transition (EMT).
In this study, we explore the effect of Snail on tumor immunity. Snail knockdown in mouse
ovarian cancer cells suppresses tumor growth in immunocompetent mice, associated with an
increase of CD8+ tumor-inﬁltrating lymphocytes and a decrease of myeloid-derived
suppressor cells (MDSCs). Snail knockdown reduces the expression of CXCR2 ligands
(CXCL1 and CXCL2), chemokines that attract MDSCs to the tumor via CXCR2. Snail
upregulates CXCR ligands through NF-kB pathway, and most likely, through direct binding to
the promoters. A CXCR2 antagonist suppresses MDSC inﬁltration and delays tumor growth
in Snail-expressing mouse tumors. Ovarian cancer patients show elevated serum CXCL1/2,
which correlates with Snail expression, MDSC inﬁltration, and short overall survival. Thus,
Snail induces cancer progression via upregulation of CXCR2 ligands and recruitment
of MDSCs. Blocking CXCR2 represents an immunological therapeutic approach to inhibit
progression of Snail-high tumors undergoing EMT.
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Emerging evidence suggests that the acquisition of invasive-ness in cancer is accompanied by the loss of epithelialfeatures and the gain of a mesenchymal phenotype, a
process known as epithelial-to-mesenchymal transition (EMT)1,2.
In previous reports, gene expression clustering in ovarian cancer
showed that the mesenchymal subtype, comprising enriched
EMT-related gene signatures, had poor survival compared to
other subtypes1,3,4. We discovered that there is decreased number
of intraepithelial CD8+ tumor-inﬁltrating lymphocytes (CD8
+TILs) in the mesenchymal subtype4. Thus, immune evasion
might be taking place in the tumor undergoing EMT, although
the mechanism of suppression of anti-tumor immunity in the
state of EMT remains unclear.
Immune evasion is one of the major hallmarks of cancer5, often
accomplished via the recruitment of immunosuppressive cells
such as myeloid-derived suppressor cells (MDSCs) or through
the expansion of an immune checkpoint signal, namely the
programmed death 1 (PD-1)/PD-1 ligand 1 (PD-L1) axis6–11.
MDSCs represent a heterogeneous immature immunosuppressive
myeloid cell population that expands during cancer progression
and has the remarkable ability to suppress T cell functions in the
tumor microenvironment7. Since MDSCs were ofﬁcially descri-
bed in 2007, an increasing number of studies have reported the
biological and clinical signiﬁcance of MDSCs6,7,12,13. We pre-
viously reported that MDSC inﬁltration was inversely correlated
with CD8+TIL numbers and shorter overall survival in advanced
ovarian cancer14. These reports indicated that MDSCs, as key
players in cancer immune evasion, might be used both as prog-
nostic factors and as therapeutic targets in cancer treatment.
Here, we focus on Snail, a key transcriptional repressor of
E-cadherin during EMT15,16, and explore the inﬂuence of Snail
on MDSC inﬁltration into ovarian tumors. Elucidating the
mechanisms of Snail-induced immune evasion leads to the
potential development of novel treatment strategies for tumor
undergoing EMT.
Results
Snail is correlated with EMT and prognosis in ovarian cancer.
We ﬁrst analyzed the dataset of high-grade serous ovarian cancer
(HGSOC) from The Cancer Genome Atlas (TCGA) (n= 266).
Application of a generic gene signature of EMT3 to score the
EMT status of the TCGA samples revealed that Snail expression
was positively correlated with EMT scores (Fig. 1a). TCGA
samples were divided into four molecular subtypes (differ-
entiated, immunoreactive, mesenchymal, and proliferative) based
on unsupervised hierarchical clustering using gene expression
analysis1. Among the four subtypes, the mesenchymal subtype,
which is associated with the poorest prognosis and has an
EMT-related expression signature, had the highest Snail
expression (Fig. 1b).
We next assessed the association between the EMT-related
molecule Snail and prognosis in 56 cases of HGSOC (48 stage III
cases and 8 stage IV cases) in Kyoto University Hospital. These
samples were classiﬁed into four groups based on the nuclear
expression of Snail, as determined by immunostaining (Fig. 1c).
Samples with scores of 0/1 or 2/3 were assigned to the Snail-low
and Snail-high groups, respectively. We ascertained the speciﬁcity
of the anti-Snail antibody we used (Supplementary Figs. 1a, b).
High Snail expression in the peritoneal dissemination was
associated with shorter overall survival (Fig. 1d). Multivariate
analysis using Cox proportional hazards regression indicated that
Snail expression in the peritoneal dissemination serve as a
negative, independent prognostic factor for overall survival




























































Fig. 1 Snail expression is related to epithelial-to-mesenchymal transition and poor prognosis in ovarian cancer. a Correlation between generic epithelial-to-
mesenchymal transition (EMT) scores for 266 high-grade serous ovarian cancer (HGSOC) samples from TCGA dataset1 and Snail expression. The EMT
signature was acquired from a previous report by Tan et al.3. Generic EMT scores were calculated following the method of single-sample Gene Set
Enrichment Analysis (ssGSEA). The correlation coefﬁcient (R) and P-value were based on Pearson’s product-moment correlation analysis; R= 0.41 P <
0.0001. b Snail expression in HGSOC samples representing four subtypes from the TCGA datasets; ***P < 0.001 and ****P < 0.0001, mesenchymal vs. the
other three subtypes based on one-way ANOVA with Tukey’s multiple comparisons test. Bars: mean and SEM. c Classiﬁcation of HGSOC as determined by
the intensity of nuclear Snail immunostaining. Cases with scores of 0/1 were assigned to the Snail-low group, whereas those with scores of 2/3 were
assigned to the Snail-high group to be used in survival analysis. Scale bars, 100 μm. d Overall survival curves for patients with HGSOC in Kyoto University
Hospital (n= 56; 48 stage III cases and 8 stage IV cases), based on Snail staining of disseminated tumors in the omentum. P= 0.021 by log-rank test
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P= 0.031; Supplementary Table 1). These results suggest that
Snail expression in the peritoneal dissemination is associated with
EMT and unfavorable prognosis in ovarian cancer.
Snail induces EMT and promotes tumor progression in mice.
To elucidate the function of Snail, we generated HM-1-shSnail
cell lines through the stable transduction of Snail-targeting two
separate shRNA vectors into the HM-1 mouse ovarian cancer cell
line. In HM-1-shsSnail cells, the expression of E-cadherin (an
epithelial marker) increased, whereas that of vimentin (a
mesenchymal marker) decreased (Fig. 2a). Cell invasion, assessed
by wound-healing and invasion assays, was suppressed in HM-1-
shSnail cells, compared to that in HM-1-control cells (Fig. 2b, c).
Snail knockdown did not affect in vitro cell proliferation (Sup-
plementary Fig. 2a). These data indicate that depletion of Snail
inhibits EMT-like characteristics.
We also established Snail-depleted (OVCAR8-shSnail) and
Snail-overexpressing (OVCA433-Snail) human ovarian cancer
cell lines. Based on the altered expression of EMT-related proteins
and changes in cell invasion capacity, it was demonstrated that
EMT was inhibited in OVCAR8-shSnail cells and promoted in
OVCA433-Snail cells (Supplementary Figs. 2b, c). Altered Snail
expression did not affect in vitro cell proliferation (Supplemen-
tary Fig. 2d). Altered Snail expression did not affect cell apoptosis
(Supplementary Fig. 2e). Collectively, these results conﬁrmed that
Snail expression induces EMT in ovarian cancer cell lines.
Next, we injected HM-1-shSnail cells subcutaneously or
intraperitoneally into immunocompetent mice. Snail depletion
inhibited tumor growth and prolonged overall survival compared
to those in control animals (Fig. 2d and Supplementary Fig. 3a).
In contrast, there was no signiﬁcant difference in tumor growth
or in overall survival between HM-1-control and HM-1-shSnail
groups in immunodeﬁcient mice (Fig. 2e and Supplementary
Fig. 3b). These data suggested that Snail facilitates tumor
progression through mechanisms that are related to tumor
immunity.
Snail increases MDSCs and suppresses anti-tumor immunity.
Microscopically, HM-1-shSnail tumors were associated with
increased CD8+TILs and decreased inﬁltration by Gr-1-positive
or CD11b-positive MDSCs (Gr-1 and CD11b, a mouse MDSC
marker) (Fig. 3a and Supplementary Figs. 4a, b). Flow cytometric
analyses of immune cells in subcutaneous tumors revealed that
the number of CD8+TILs and the percentage of IFNγ-positive
CD8+TILs signiﬁcantly increased in HM-1-shSnail samples
(P < 0.001, unpaired t-test), whereas the number of MDSCs sig-
niﬁcantly decreased (P < 0.01, unpaired t-test) (Fig. 3b). Regard-
ing MDSC subpopulations, granulocytic-MDSCs (G-MDSCs)
were decreased in HM-1-shSnail tumors compared to levels in
control tumors; however, there was no signiﬁcant difference in
terms of the numbers of monocytic-MDSCs (M-MDSCs) and
tumor-associated macrophages (TAMs) (Supplementary Fig. 4c).
CD49b+ cells (CD49b, a mouse natural killer (NK) cell marker)
were increased in Snail-depleted tumors (Supplementary Fig. 5),
although Snail interference did not suppress tumor growth of
immunodeﬁcient nude mice with the functioning NK cells
(Fig. 2e).
We next examined the relationship between Snail and MDSCs
in clinical ovarian cancer samples in Kyoto University Hospital.
Using immunostaining, we evaluated the expression of CD33, a
marker of human MDSCs, in primary ovarian tumors and in

























































































Fig. 2 Snail suppresses tumor progression and is associated with tumor immunity. a Western blot of HM-1-control and HM-1-shSnail cells. CDH1:
E-Cadherin, VIM vimentin. b Invasion of HM-1-control and HM-1-shSnail cells; n= 5. c Wound healing of HM-1-control and HM-1-shSnail cells. Data
represent the percentage of wound width (24 h) relative to that at 0 h; n= 6. d Growth curves of HM-1-control and HM-1-shSnail subcutaneous tumors in
immunocompetent mice. P-values represent signiﬁcance between two groups at day 31; n= 6. e Growth curves of HM-1-control and HM-1-shSnail
subcutaneous tumors from immunodeﬁcient nude mice; n= 6; NS no signiﬁcant difference between two groups at day 23. *P < 0.05, **P < 0.01, and
***P < 0.001 (one-way ANOVA with Tukey’s multiple comparisons test in b–e). Averaged data are presented as the mean ± SEM
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signiﬁcant correlation with the number of CD33+ cells (P=
0.0082, Pearson’s product-moment correlation analysis) (Fig. 3d).
Human MDSCs are deﬁned as CD33+CD11b+LIN−HLA-DR
−/low cells. Flow cytometry revealed that 85.1% of CD33+ cells
were conﬁned to the CD33+CD11b+LIN− HLA-DR−/low type in
ovarian tumor samples, and these cells expressed high levels of
Arginase 1 regardless of HLA-DR expression (Supplementary
Fig. 6). To examine whether intratumoral CD33+ cells suppress T
cell proliferation, we isolated CD33+ cells from primary ovarian
cancer samples and incubated the isolated cells with proliferating
T cells. CD33+ cells markedly inhibited T cell proliferation
(Supplementary Fig. 7). Thus, CD33+ cells were conﬁrmed to
represent MDSCs. These results demonstrated that Snail induces
MDSC inﬁltration and suppresses anti-tumor immunity.
CXCL1 and CXCL2 are expressed in Snail-high ovarian can-
cers. To discover the factor responsible for increased intratumoral
MDSCs in Snail-high tumors, we conducted microarray analysis
of HM-1-control (n= 3) and HM-1-shSnail (sh1; n= 2 and sh2;
n= 2) samples. This yielded 81 signiﬁcantly downregulated genes
and 19 signiﬁcantly upregulated genes (changes of more than 2-
fold and P < 0.0005 by one-way ANOVA; Supplementary
Tables 2, 3). Particularly, CXCL2 and CXCL5 were down-
regulated more than 10-fold in HM-1-shSnail tumors (Fig. 4a).
CXCL2 and CXCL5 are CXCR2 ligands. CXCR2 ligands have
been reported to induce MDSC inﬁltration through CXCR217. As
expected, CXCR2 was highly expressed on MDSCs, especially G-
MDSCs, in ascitic ﬂuid samples from human ovarian cancer
(Supplementary Figs. 8a, b).
Next, we assessed whether Snail alters CXCR2 ligand
expression in human samples and cell lines. Based on TCGA
data, Snail expression was correlated with the expression of
CXCR2 ligands, speciﬁcally CXCL1, CXCL2 and, to a lesser
extent, CXCL5 (Fig. 4b). Subsequently, we examined the
expression of CXCR2 ligands in human ovarian cell lines by
reverse transcription polymerase chain reaction (RT-PCR).
CXCL1, CXCL2, and CXCL5 expression was lower in OVCAR8-
shSnail cells than in OVCAR8-control cells (Fig. 4c). OVCA433-
Snail cells exhibited higher expression of CXCR2 ligands than
OVCA433-control cells (Fig. 4c). Two more human ovarian
cancer cell lines (A1847-shSnail and JHOS2-Snail) were used to
validate that the chemokine levels were affected by Snail, and we
obtained similar results (Supplementary Fig. 9). We also
examined cytokine levels in supernatants of the human ovarian
cancer cell lines by ELISA. Levels of CXCL1 and CXCL2 in
OVCAR8-shSnail cells were lower than those in OVCAR8-
control cells, whereas there was no signiﬁcant difference between
the two groups in terms of CXCL5 levels (Fig. 4d). CXCL1 and
CXCL2 levels increased in OVCA433-Snail cells compared to
those in OVCA433-control cells, whereas CXCL5 was not
detectable in both groups (Fig. 4e).
Next, we assessed the expression of these chemokines in the
mouse ovarian cancer cell line HM-1. RT-PCR showed that HM-
1-shSnail cells expressed lower levels of Cxcl1, Cxcl2, and Cxcl5
(Fig. 4f). In subcutaneous mouse tumors, CXCL1 and CXCL2
levels were lower in HM-1-shSnail tumors, whereas CXCL5 levels
were not different (Fig. 4g). CXCL1, CXCL2, and CXCL5
concentrations in the blood were lower in mice with HM-1-
shSnail tumors (Fig. 4h). Together, these data demonstrate that
Snail increases the expression of CXCL1 and CXCL2, chemokines
known to induce MDSC inﬁltration.
Snail induces CXCL1/CXCL2 expression via the NF-κΒ path-
way. To investigate the mechanism through which Snail induces
CXCL1 and CXCL2 expression, we reevaluated the microarray
data comparing HM-1-control to HM-1-shSnail tumors and
analyzed the 81 downregulated genes by Gene Ontology (GO)






















































































































Fig. 3 Snail is associated with increased intratumoral myeloid-derived suppressor cells. a Immunostained cell count in HM-1-control and HM-1-shSnail
(sh1) subcutaneous tumors from immunocompetent mice. HPF high power ﬁeld; n= 5–6. CD8+ (left), Gr-1+ (middle), and CD11b+ (right). b Flow
cytometry of HM-1-control and HM-1-shSnail (sh1) subcutaneous tumors from immunocompetent mice. The percentage of positive cells is plotted; n= 6.
CD8+ (left; CD3+CD4−CD8+), intracellular IFNγ (middle; IFNγ CD3+CD8+), and MDSC (right; CD45+Gr-1+CD11b+). c Representative image showing
CD33 expression (a marker of human MDSC) in peritoneal dissemination of human high-grade serous ovarian cancer (HGSOC). Scale bar, 100 μm. d
Correlation between inﬁltration of CD33+ cells and Snail expression in corresponding disseminated tumors in the omentum (R= 0.35, P= 0.0082) of
HGSOC; n= 56; Pearson’s product-moment correlation analysis. *P < 0.05, **P < 0.01, and ***P < 0.001 (unpaired t-test in a and b). Averaged data are
presented as the mean ± SEM
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was among the downregulated pathways in HM-1-shSnail sam-
ples. It has been previously reported that the NF-κB pathway
activates CXCL1 and CXCL2 gene transcription18. We hypothe-
sized that the NF-κB pathway would be activated during Snail-
induced EMT, which would enhance CXCL1 and CXCL2
expression. To further investigate this possibility, we analyzed
nuclear phospho-p65 levels in ovarian cancer cell lines by western
blot analysis. Phospho-p65, a main factor of the canonical NF-κB
pathway, was decreased in Snail-depleted cell lines such as
HM-1-shSnail and OVCAR8-shSnail, and was increased in the
Snail-overexpressing cell line OVCA433-Snail (Fig. 5a). RelB, a
factor involved in the non-canonical NF-κB pathway, was
unchanged in Snail-depleted cell lines. The results suggest that the
canonical NF-κB pathway is activated by Snail. We next
conﬁrmed that NF-κB promotes CXCL1 and CXCL2 gene tran-
scription. When treated with the NF-κB inhibitor, BAY11-7082,
Cxcl1 and Cxcl2 expression decreased in HM-1-control cells
(Fig. 5b). CXCL1 and CXCL2 expression also decreased in
OVCAR8-control cells (Fig. 5b). However, a signiﬁcant difference
in CXCL1 levels remained between BAY11-7082-treated control
and Snail-depleted cells (P < 0.01, one-way ANOVA with
Turkey’s multiple comparisons test) (Fig. 5b), indicating that

























































































(fold change ≥ 10; CXCL2, CXCL5, CCL2, Gpr149)
T cell migration (GO:0072678)
Chemokine-mediated signaling pathway (GO:0070098)
Negative regulation of I-kappaB kinase/NF-kappaB signaling
(GO:0043124)











































































































































































































Fig. 4 CXCR2 ligands are highly expressed in Snail-high ovarian tumors. a GO (Gene Ontology) term analysis of DNA microarray data obtained from HM-1-
control (n= 3) and HM-1-shSnail (sh1; n= 2 and sh2; n= 2) cells. Genes that were signiﬁcantly downregulated were used for GO term analysis. Genes are
listed in Supplementary Table 2. b Snail expression was correlated with the expression of CXCR2 ligands (CXCL1; upper left, P < 0.0001, CXCL2; upper
right, P < 0.001, and CXCL5; lower left, P < 0.05) in TCGA samples (n= 266). Pearson’s product-moment correlation analysis. c Reverse transcription
polymerase chain reaction (RT-PCR) of human ovarian cancer cell lines, OVCAR8 and OVCAR8-shSnail (left), and OVCA433 and OVCA433-Snail (right);
n= 4. d, e ELISA of cell supernatants of human ovarian cancer cell lines, d OVCAR8 and OVCAR8-shSnail, and e OVCA433 and OVCA433-Snail; n= 6. f
RT-PCR of HM-1-control and HM-1-shSnail cells; n= 5. g, h Levels of CXCL1, CXCL2, and CXCL5 in subcutaneous tumors (g) and in blood (h) taken from
mice bearing HM-1-control and HM-1-shSnail tumors; n= 6. *P < 0.05, **P < 0.01, and ***P < 0.001 (unpaired t-test in c–e, g, h; one-way ANOVA with
Tukey’s multiple comparisons test in f). Averaged data are presented as the mean ± SEM
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We also considered the possibility of direct control of CXCL1
and CXCL2 gene transcription by Snail. A published dataset of
chromatin immunoprecipitation sequencing (ChIP-seq) using an
anti-Snail antibody (GSE61198) was analyzed to identify regions
of increased sequence read tag density within the 5-kbp upstream
and downstream sequences relative to the transcriptional start site
(TSS) of Cxcl1 and Cxcl219. It was revealed that Snail occupied the
promoter of Cxcl1, and to a lesser extent Cxcl2 (Supplementary
Fig. 10). The binding of Snail appeared to activate Cxcl1 and
Cxcl2 expression, because knockdown of Snail in HM-1 led to
downregulation of Cxcl1 and Cxcl2. To investigate this possibility
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Fig. 5 Snail induces CXCL1 and CXCL2 via the NF-κB pathway and possibly via the direct binding to their promoters. a Western blotting of nuclear Snail,
phosphorylated p65 (phospho-p65), p65 and RelB from HM-1, OVCAR8 and OVCA433 cells. HDAC1 was used as control. b Reverse transcription
polymerase chain reaction (RT-PCR) to analyze the expression of Cxcl1 and Cxcl2 in HM-1-control and HM-1-shSnail cells (left), and the expression of
CXCL1 and CXCL2 in OVCAR8-control and OVCAR8-shSnail cells (right), treated with or without BAY11-7082 (NF-κB inhibitor) at 10 μM for 24 h; n= 4. c
Schematic representation of CXCL1 and CXCL2 promoter organization, and the corresponding luciferase reporter constructs pGL-CXCL1 (1523 bp: −1523 to
+110 bp, 984 bp: −984 to +110 bp, 300 bp: −300 to +110 bp) and pGL-CXCL2 (1606bp: −1606 to +104 bp, 942 bp: −942 to +104 bp, 457 bp: −457 to
+104 bp). TSS transcriptional start site, E1 exon1, and Luc luciferase. The black bars indicate E-boxes (CANNTG), which are the binding sites of Snail. d
Luciferase reporter assays to analyze the activity of the pGL-CXCL1 and pGL-CXCL2 promoter constructs in 293FT-control and 293FT-shSnail cells.
Relative luciferase activities are shown; n= 5. *P < 0.05, **P < 0.01, and ***P < 0.001 (one-way ANOVA with Tukey’s multiple comparisons test in b;
unpaired t-test in d). Averaged data are presented as the mean ± SEM
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03966-7
6 NATURE COMMUNICATIONS |  (2018) 9:1685 | DOI: 10.1038/s41467-018-03966-7 | www.nature.com/naturecommunications
discovered E-boxes (CANNTG; binding sites for Snail) near their
TSS and developed the corresponding luciferase reporter
constructs (pGL-CXCL1-1523bp, 984 bp, 300 bp, pGL-CXCL2-
1606bp, 942 bp, and 457 bp). Transfection of shSnail decreased
the promoter activity of CXCL1-1523bp, CXCL1-984bp, and
CXCL2-1606bp constructs (Fig. 5d), indicating that Snail might
bind to the CXCL1 promoter region from −984bp to −301bp and
to the CXCL2 promoter region from −1606bp to −943bp. These
results suggest that Snail induces CXCL1 and CXCL2 expression
through the NF-kB pathway, and possibly via direct transcrip-
tional activation.
CXCR2 ligands attract MDSCs and promote tumor growth.
Next, we examined the effect of CXCR2 ligands on MDSC che-
motaxis. The migration of tumor-isolated MDSCs from HM-1-
bearing mice was augmented by CXCL1 and CXCL2 in a dose-
dependent manner (Fig. 6a). G-MDSCs were mainly attracted by
CXCR2 ligands (Supplementary Fig. 11). Treatment with CXCR2
antagonist (SB265610) inhibited MDSC chemotaxis induced by
chemokines (Fig. 6b). As in mouse MDSCs, MDSCs from human
ovarian cancer ascitic ﬂuid samples were attracted by CXCL1,
CXCL2, and CXCL5, and a CXCR2 antagonist inhibited this
migration (Fig. 6c, d). We made sure that MDSCs of tumor-
bearing mice inhibited T cell proliferation (Supplementary
Fig. 12). These data demonstrate that CXCR2 ligands induce
MDSC chemotaxis through CXCR2.
In vivo G-MDSC depletion using an anti-Ly6G-antibody
inhibited tumor growth in HM-1 tumor-bearing mice, but not
in HM-1-shSnail tumor-bearing mice (Fig. 7a). MDSCs decreased
and the CD8+T cell: MDSC ratio increased in anti-Ly6G
antibody-treated HM-1-control tumors (Fig. 7b). G-MDSC
depletion did not affect intratumoral MDSCs of HM-1-shSnail
tumor-bearing mice (Fig. 7c). Moreover, in vivo treatment using a
CXCR2 antagonist (SB265610) inhibited tumor growth in HM-1
tumor-bearing mice, but not in HM-1-shSnail tumor-bearing
mice (Fig. 7d). MDSCs decreased and the CD8+T cell: MDSC
ratio increased in SB265610-treated HM-1-control tumors
(Fig. 7e). There were no signiﬁcant differences in these
parameters when HM-1-shSnail tumor-bearing mice were treated
with the CXCR2 antagonist (Fig. 7f). As expected, in a model of
peritoneal dissemination, SB265610 signiﬁcantly prolonged over-
all survival (P= 0.016, Log-rank test) (Supplementary Fig. 13).
These results suggest that the CXCR2 antagonist reverse
immunosuppression through the inhibition of G-MDSC migra-
tion to the tumor, thereby inhibiting tumor growth.
CXCR2 ligand levels correlates with unfavorable prognosis.
Finally, we investigated the effect of CXCL1 and CXCL2 in
clinical ovarian cancer samples. We measured the levels of
CXCR2 ligands in serum samples from ovarian cancer patients
(n= 26), and compared them to those of female healthy donors
(n= 8). Ovarian cancer patients showed signiﬁcant increases in
both CXCL1 and CXCL2 compared to those in healthy donors
(Fig. 8a). There was a signiﬁcant correlation between CXCL1 and
CXCL2 levels (P= 0.0002, Pearson’s product-moment correlation
analysis) (Fig. 8b).
We then sought to investigate the relationship between
intratumoral MDSCs and serum CXCL1 and CXCL2 levels.
Peritoneal disseminations (n= 12), from patients in which serum
levels of CXCR2 ligands had been measured, were immunos-
tained with CD33. Serum CXCL1 levels were associated with the
number of CD33+ cells (Fig. 8c). Serum CXCL2 levels were not
associated with CD33 inﬁltration, perhaps due to the small
sample number (Fig. 8c). There was no correlation between
serum CXCR2 ligand levels and CD8+, CD4+, and FOXP3+ cells
(Supplementary Fig. 14). We further analyzed Snail expression by
nuclear immunostaining in peritoneal dissemination samples.
Snail expression showed a correlation with serum CXCL1 levels
(Fig. 8d). MDSCs in PBMCs were also correlated with Snail
expression in peritoneal dissemination samples and serum
CXCL1 levels (Supplementary Fig. 15).
Finally, we investigated the association between serum
concentrations of CXCR2 ligands and overall survival in ovarian
cancer patients. Cases with high CXCR2 ligand levels were
associated with a signiﬁcantly poorer prognosis compared to
those with low CXCR2 ligands (CXCL1, P= 0.0005, log-rank test,
Fig. 8e; CXCL2, P= 0.0008, log-rank test, Fig. 8f). These results







































































































































































































Fig. 6 CXCR2 ligands induce myeloid-derived suppressor cell inﬁltration. a Chemotaxis of mouse MDSCs, from subcutaneous tumor of HM-1 tumor-
bearing mice, in response to CXCL1, CXCL2, and CXCL5; n= 4. b Chemotaxis of mouse MDSCs, from subcutaneous tumor of HM-1 tumor-bearing mice,
pre-treated with SB265610 (CXCR2 antagonist) at each concentration in the presence of each CXCR2 ligands (at 100 ng/mL); n= 4. c Chemotaxis
response of MDSCs, from human ovarian cancer ascites, to CXCL1, CXCL2, and CXCL5. The chemotaxis index is shown; n= 4. d Chemotaxis response of
human MDSCs treated with SB265610 at each concentration in the presence of each CXCR2 ligands; n= 4. *P < 0.05, **P < 0.01, and ***P < 0.001 (one-
way ANOVA with Tukey’s multiple comparisons test in a–d)
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intratumoral MDSC inﬁltration and Snail expression, and are
associated with poor prognosis.
Discussion
EMT has been widely accepted as a key process for tumor
invasion and metastasis, since the loose cell–cell contacts and
high motility derived from EMT facilitate tumor cell detachment
from basement membrane and tumor invasion into the sur-
rounding stroma or vessels16,20. EMT affects various character-
istics of the tumor such as stemness, cell–cell junction, apoptosis,
neuronal differentiation, or immune system process21. Therefore,
multiple chemical drugs targeting EMT have been developed for
cancer therapy22. However, the relationship between EMT and
immune evasion remained unclear.
Snail, a key transcriptional repressor of E-cadherin during
EMT, has a pivotal role in cancer progression15,16. In the present
study, the immunological effect of Snail on tumor micro-
environment in ovarian cancer is explored. We showed that Snail
induces intratumoral trafﬁcking of MDSCs via upregulation of
CXCR2 ligands. Surprisingly, ovarian cancer mouse model
demonstrated that Snail facilitates tumor progression only in
immunocompetent mice, indicating that the tumor-promoting
mechanisms of Snail are largely related to tumor immunity
(Fig. 2). In our microarray data, immune-associated pathways
were downregulated by Snail knockdown (Fig. 4a). Analysis of
TCGA ovarian cancer datasets indicates that Snail is correlated
with many cytokines including CXCR2 ligands (Fig. 4b). Some
reports have shown that Snail induces other immunosuppressive
cells such as regulatory T cells or TAMs23,24. Our ﬁndings and
these reports support the idea that Snail has role in multiple
functions including immune system, and Snail is a crossroad of
the two hallmarks of cancer, EMT, and immune evasion.
Here, we focused on CXCL1 and CXCL2, which function as
chemokines to attract MDSCs to the tumor, since Snail knock-
down attenuated intratumoral MDSC which suppressed CD8+T
cell proliferation (Fig. 3, Supplementary Figs. 4, 12). Interestingly,
MDSCs are also known to promote metastasis by inducing
EMT25. Together with our data, intratumoral MDSC inﬁltration
induced by Snail accelerates EMT and leads to further tumor
progression. Blocking this malicious cycle, for example with a
CXCR2 antagonist, would be a promising treatment strategy. We
demonstrated that the CXCR2 antagonist SB265610 suppresses
the recruitment of G-MDSCs to the tumor and thereby inhibits
tumor progression (Fig. 7 and Supplementary Fig. 13). Since
G-MDSCs mainly express CXCR2 in human samples
(Supplementary Fig. 8), a CXCR2 antagonist could be an effective
treatment for ovarian cancer patients. However, blockade of
CXCR2 largely but not completely inhibited tumor growth,
suggesting that Snail might activate other factors involved in anti-
tumor immunity, and the issue requires further investigation.
Serum CXCL1 and CXCL2 levels are elevated in ovarian cancer
patients and are associated with intratumoral MDSC inﬁltration
(Fig. 8). Furthermore, serum CXCL1 and CXCL2 protein levels
are associated with poor prognosis (Fig. 8). These data indicate
that serum chemokines represent a measurable marker that
reﬂects MDSC inﬁltration, and could be used to estimate immune
status of the tumor microenvironment, in place of tumor speci-
mens acquired by operation or biopsy. Some researchers have
reported that the expression of CXCL1 and CXCL2 is correlated
with tumor size, metastasis, and decreased overall survival in










































































































































































































































Fig. 7 A CXCR2 antagonist inhibits tumor progression by Snail. a Tumor growth in mice subcutaneously injected with HM-1-control cells or HM-1-shSnail
cells, treated with anti-Ly6G antibody (400 µg/body) or IgG twice a week from day 1 after tumor inoculation. P-values represent signiﬁcance between two
groups at day 19; n= 5–6. b Flow cytometric analyses of subcutaneous HM-1-control tumors treated with anti-Ly6G antibody or IgG at day 19. Percentage
of positive cells relative to total cells is plotted. MDSCs (left) and CD8+T cells/MDSCs (right); n= 6. c Flow cytometric analyses of subcutaneous HM-1-
shSnail tumors treated with anti-Ly6G antibody or IgG at day 19. The percentage of positive cells relative to total cell count is plotted. MDSCs (left) and
CD8+T cells/MDSCs (right); n= 5–6. d Tumor growth in mice subcutaneously injected with HM-1-control cells or HM-1-shSnail cells, treated with
SB265610 (2 mg/kg body weight) or PBS six times a week from day 1 after tumor inoculation. P-values represent signiﬁcance between two groups at day
21; n= 4–6. e Flow cytometric analyses of subcutaneous HM-1-control tumors treated with SB265610 or PBS at day 21. Percentage of positive cells relative
to total cells is plotted. MDSCs (left) and CD8+T cells/MDSCs (right); n= 5-6. f Flow cytometric analyses of subcutaneous HM-1-shSnail tumors treated
with SB265610 or PBS at day 21. The percentage of positive cells relative to total cell count is plotted. MDSCs (left) and CD8+T cells/MDSCs (right); n=
4–5. *P < 0.05, **P < 0.01 and, ***P < 0.001 (unpaired t-test in a–f)
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patients26–30. Although multivariate analysis failed to demon-
strate that the expression of these chemokines is an independent
predictor of unfavorable prognosis in ovarian cancer, elevated
chemokine levels were related to Snail and MDSC inﬁltration
(Fig. 8). To overcome the possible limitation of small sample size,
it is necessary to conduct larger clinical studies in the future to
evaluate serum CXCL1 and CXCL2 as biomarkers.
In conclusion, Snail upregulates the expression of CXCL1/2 and
enhance MDSC tumor inﬁltration via CXCR2; MDSCs were shown
to inhibit anti-tumor immunity and promote tumor progression.
CXCR2 and its ligands could thus be a therapeutic target for tumors
with high Snail expression. These ﬁndings provide new insights into
the mechanism that might link EMT to tumor immunity.
Methods
Cell lines. The OV2944-HM-1 (HM-1) mouse ovarian cancer cell line and JHOS2
were purchased from RIKEN BioResource Center and were cultured as previously
described in ref. 14,31. Human ovarian cancer cell lines (OVCAR8, OVCA433, and
A1847) were provided by Dr. Susan K. Murphy from Duke University. These cells
were cultured and maintained in RPMI1640 (Invitrogen, Carlsbad, CA, USA)
supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 g/mL
streptomycin in an atmosphere containing 5% CO2 at 37 °C. 293FT cells were
purchased from Thermo Fisher Scientiﬁc (Waltham, MA, USA) and cultured as
described in ref. 32. Throughout this study, we used cell lines that were passaged
fewer than 30 times. All cell lines were regularly tested for mycoplasma
contamination.
shRNA vectors and ORF. HM-1-shSnail cells were generated by lentiviral
transfection with short hairpin RNAs (shRNAs) targeting Snail using Mouse GIPZ
Lentiviral shRNA viral particles (GE Healthcare UK, Buckinghamshire, England;
sh1, clone ID V3LMM_523301, gene target sequence AGTTTATTGATATTCA
ATA; sh2, clone ID V3LMM_523299, gene target sequence TGGTTAATTTA
TATACTAA).
OVCAR8-shSnail, A1847-shSnail, and 293FT-shSnail cell lines were generated
by Human GIPZ Lentiviral shRNA viral particles (GE Healthcare UK; clone ID
V3LHS_328732, gene target sequence AGCGAGCTGCAGGACTCTA). Control
cell lines, HM-1-control, OVCAR8-control, and 293FT-control, were generated
through the transfection of a non-silencing, control shRNA (GE Healthcare UK;
clone ID RHS4348).
The Snail-overexpressing cell lines, OVCA433-Snail, and JHOS2-Snail were
generated by lentiviral transfection of an open reading frame using Precision
LentiORF viral particles (GE Healthcare UK; clone ID PLOHS_100004229). The
control cell lines, OVCA433-control, and JHOS2-control, were generated by
transfecting a non-silencing, control shRNA (GE Healthcare UK; clone ID OHS5833).
RNA extraction and real-time quantitative PCR. Total RNA was extracted from
cells and frozen tissues using an RNeasy Mini Kit (Qiagen, Venlo, Netherlands). A
Transcriptor High Fidelity cDNA Synthesis Kit (Roche Diagnostics, Roswell, GA,
USA) was used for cDNA synthesis. For RT-PCR, cDNA was ampliﬁed using a
thermal cycler. RT-PCR was performed by ampliﬁcation of the target genes and
Gapdh mRNA as a reference gene using a Light Cycler 480-II (Roche Diagnostics).
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Fig. 8 Elevated levels of serum CXCL1 and CXCL2 reﬂect intratumoral MDSCs and are associated with poor prognosis in ovarian cancer patients. a Serum
concentration of CXCL1 (left) and CXCL2 (right) in ovarian cancer patients (n= 26) vs. that in healthy donors (n= 8); mean ± SEM; ***P < 0.001 by
unpaired t-test. b Correlation between CXCL1 and CXCL2 serum concentrations in ovarian cancer patients (n= 26); P= 0.0002, R= 0.67. Pearson’s
product-moment correlation analysis. c Correlation between serum CXCL1 (left; P= 0.018) and CXCL2 (right; P= 0.09) levels and inﬁltration of CD33+
cells in peritoneal disseminations; n= 12; Pearson’s product-moment correlation analysis. d Correlation between serum CXCL1 (left; P= 0.049) and
CXCL2 (right; P= 0.080) levels and Snail staining scores; n= 12; Pearson’s product-moment correlation analysis. e Overall survival of ovarian cancer
patients, comparing the high-serum CXCL1 group (n= 12) to the low-serum CXCL1 group (n= 14). Cut-off levels, 42.83 pg/ml; AUC= 0.6842. Hazard
ratio, 15.08; 95% conﬁdence interval (CI), 3.859–102.9; P= 0.0005 by log-rank test. f Overall survival of ovarian cancer patients, comparing the high-
serum CXCL2 group (n= 13) to the low-serum CXCL2 group (n= 13). Cut-off levels, 93.57 pg/ml; AUC= 0.6767. Hazard ratio, 13.87; 95% conﬁdence
interval (CI), 3.56–89.72; P= 0.0008 by log-rank test
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Relative target gene expression was estimated by dividing the threshold cycle (CT)
value of the target gene by the CT value for Gapdh mRNA.
Immunoblotting. Cell pellets were lysed with 1× RIPA buffer (Thermo Fisher
Scientiﬁc) containing a protease inhibitor cocktail (Nacalai Tesque, Kyoto, Japan)
and a phosphatase inhibitor cocktail (Nacalai Tesque). Nuclear proteins were
collected using NE-PER Nuclear and cytoplasmic extraction reagents (Thermo
Fisher Scientiﬁc) according to the manufacturer’s protocol. Proteins were subse-
quently separated by SDS-PAGE and transferred to nitrocellulose membranes.
Membranes were immunoblotted with the following antibodies: Rabbit anti-NF-κB
p65 (phospho S536) antibody (ab28856; 1:500 dilution; Abcam), rabbit anti-NF-κB
p65 antibody (#8242; 1:1000 dilution; cell signaling), rabbit anti-RelB antibody
(#4922; 1:1000 dilution; cell signaling), rabbit anti-SNAIL antibody (ab180714;
1:1000 dilution; Abcam), rabbit anti-E-cadherin antibody (sc-7870; 1:500 dilution;
Santa Cruz), mouse anti-Vimentin antibody (MA5-11883; 1:200 dilution; Invi-
trogen), mouse anti-GAPDH antibody (ab9484; 1:1000 dilution; Abcam), and
rabbit anti-HDAC1 antibody (ab109411 1:1000 dilution; Abcam). The bands were
visualized using Molecular Imager Gel DocTMXR+ and ChemiDocTMXRS+
Systems with Image Lab 2.0 software (Bio-Rad). Uncropped scans of the blotted
gels with the weight markers are shown in Supplementary Fig. 16.
ELISA. Tumor tissue was weighed, treated in a bead homogenizer, and sonicated in
1× RIPA buffer (Thermo Fisher Scientiﬁc) containing a protease inhibitor cocktail
(Nacalai Tesque) and a phosphatase inhibitor cocktail (Nacalai Tesque), and was
centrifuged at 16,000×g for 10 min at 4 °C. Mouse blood was obtained from tumor-
bearing mice, and was allowed to clot for 30 min on ice, before being centrifuged at
16,000×g for 10 min at 4 °C and serum was aspirated. Samples were subjected to
ELISA analysis. Mouse CXCL1, CXCL2, and CXCL5 protein levels were measured
by mouse Quantikine ELISA kits for CXCL1, CXCL2, or CXCL5 (R&D systems,
Minneapolis, MN, USA) according to the manufacturer’s protocols. Human
CXCL1, CXCL2, and CXCL5 protein levels in culture supernatants and patient
serum samples were measured using Human ABTS ELISA Development Kits for
CXCL1 or CXCL2 (PeproTech, Rocky Hill, NJ, USA) and a human CXCL5
Quantikine ELISA kit according to the manufacturer’s protocols.
Cell proliferation assays. Water soluble tetrazolium-8 assays were performed
using Cell Count Reagent SF (Nacalai Tesque, Kyoto, Japan) according to the
manufacturer’s protocol, and the proliferation rate for each cell line was calculated
and plotted.
Wound-healing assays. Cells were seeded on 6-well plates and grown to con-
ﬂuency. Subsequently, the monolayer was gently scratched with a pipette tip to
create a mechanical wound. Images were taken at 0 and 24 h using a microscope.
Invasion assays. Cells were seeded in Boyden chambers with 8.0-μm pore PET
membranes (Becton Dickinson, Franklin Lakes, NJ, USA) that were coated with
Matrigel. After 24 h, Boyden chamber membranes were ﬁxed with 4% PFA, per-
meabilized with 99% methanol, and stained with hematoxylin. The number of cells
that invaded through the membrane was visually counted at a magniﬁcation of
×200 from ﬁve ﬁelds and the average number was calculated as previously
described in ref. 33. The invasion rate for each cell line was calculated and plotted.
Apoptosis assay. Cells were seeded on 24-well plates and grown to conﬂuency.
Cells were harvested and analyzed by a MACS Quant (Miltenyi Biotec, Bergisch
Galdbach, Germany) following staining with APC-labeled annexin V antibody (BD
Pharmingen/BD Biosciences, Franklin Lakes, NJ, USA) and propidium iodide
according to the manufacturer’s protocol.
NF-κΒ inhibitor treatment assays. A total of 1 × 105 HM-1 cells in 24-well dishes
or 1 × 105 OVCAR8 cells in 12-well dishes were treated with BAY11-7082 (Santa
Cruz Biotechnology, Dallas, TX, USA) at 10 μM for 24 h. Total RNA was extracted
from cells and frozen tissues using an RNeasy Mini Kit (Qiagen). RT-PCR was then
performed as previously described.
Luciferase reporter assays. A DNA fragment for the human cytomegalovirus
minimal promoter was inserted between the Bgl II and Hind III sites of pGL3
promoter vector (Promega, Madison, WI, USA), and the resultant pGL3/CMVmp
plasmid was provided by Prof. Harada and Dr. Katagiri. The regulatory regions of
the CXCL1/CXCL2 gene (−1523/−984/−300 to +110, or −1606/−942/−450 to
+104, respectively, of the surrounding the TSS) were cloned by PCR ampliﬁcation
of genomic DNA and then inserted between the Kpn I and Xho I sites of the pGL3/
CMVmp plasmid to generate CXCL1/CXCL2-Luc reporter constructs.
Luciferase reporter assays were performed by transfecting the reporter construct
into 293FT-shSnail cells. The pRL-CMV vector was co-transfected in each
experiment as an internal control for transfection efﬁciency. At 48 h post-
transfection, luciferase activities were measured using the Dual-Luciferase Reporter
Assay System (Promega) according to the manufacturer’s protocols.
Mice. Female B6C3F1 (C57BL6×C3/He F1) mice were purchased from CLEA
Japan (Tokyo, Japan) and used in immunocompetent mice experiments. Female
ICR-nu (Crlj: CD1-Foxn1nu) mice was purchased from Charles River Japan
(Yokohama, Japan) and used in immunodeﬁcient mice experiments. Animals were
maintained under speciﬁc pathogen-free conditions.
Animal experiments. A total of 1 × 106 HM-1-shSnail (sh1) or HM-1-control cells
were inoculated subcutaneously into the right ﬂank or injected into the abdominal
cavity of 6–8-week-old female B6C3F1 mice and nude mice. Anti-Ly6G antibody
(clone 1A8; BioXcell, West Lebanon, NH, USA) or mouse IgG2a (clone 2A3;
BioXcell) treatment was initiated 1 day after tumor cell inoculation and was
administered intraperitoneally twice a week (400 μg per body) as previously
describedin ref. 34. CXCR2 antagonist treatment was initiated 1 day after tumor cell
inoculation and was administered intraperitoneally six times a week (SB265610: 2
mg/kg body weight; R&D systems) as previously described in ref. 35. Mice were
euthanized before becoming moribund. The subcutaneous tumor size and body
weight were measured twice a week and tumor volumes were calculated as follows:
volume= LD × SD2 × 0.5, where LD is the long diameter (mm) and SD (mm) is the
short diameter of the tumor. Cages of mice were allocated to experimental groups
by random draw. The investigator was not blinded to the group allocation. Sample
sizes were chosen to assure reproducibility of the experiments in accordance with
the replacement, reduction, and reﬁnement principles of animal ethics regulation.
All animal studies were approved by Kyoto University Animal Research
Committee.
Immunohistochemical analysis of mouse tumors. Tumor cryosections (6-μm-
thick) were stained with anti-CD8 (clone YTS169.4; Abcam), anti-Gr-1 (clone
RB6-8C5; BD Pharmingen), or anti-CD11b (clone M1/70; BioLegend, San Diego,
CA, USA) antibodies as previously described in ref. 14. CD8+, Gr-1+, and CD11b+
cell inﬁltration into omental tumors was quantiﬁed and evaluated.
Immunohistochemical analysis of human clinical samples. Immunostaining was
performed using the streptavidin-biotin-peroxidase method as previously described
in ref. 9. Double immunostaining was performed using MACH2 double stain
polymer detection reagent (BRR525; BioCare Medical, CA, USA) according to the
manufacture’s protocol. For Snail, CD33, p53, CD8, CD4, and FOXP3, the samples
were incubated with a rabbit anti-SNAIL polyclonal antibody (ab180714; 1:1000
dilution; Abcam, Cambridge, UK), mouse anti-CD33 monoclonal antibody (clone
PWS44; 1:200 dilution; Leica Biosystems, Nussloch, Germany), mouse anti-p53
monoclonal antibody (clone DO-7; 1:100 dilution; Agilent, Santa Clara, CA, USA),
mouse anti-CD8 monoclonal antibody (clone; C8/144B; 1:100 dilution; Nichirei
Biosciences, Tokyo, Japan), rabbit anti-CD4 monoclonal antibody (clone; SP35;
1:100 dilution; Cell-Marque, Rocklin, CA, USA), and mouse anti-FOXP3 mono-
clonal antibody (clone; 236AE/7; 1:100 dilution; Invitrogen). Samples were classi-
ﬁed according to the intensity of Snail staining and scored as follows: 0, negative; 1,
weak; 2, moderate, and 3, strong expression as shown in Fig. 1c. Samples with
heterogeneous staining were scored based on intensity in the largest stained area.
Scores of 0/1 and 2/3 were deﬁned as Snail-low and Snail-high, respectively.
Samples with heterogeneous staining were scored based on the intensity in the
largest stained area. Tumor-inﬁltrating immune cells were evaluated as previously
described in ref. 14. Brieﬂy, intratumoral CD33+ cells were counted from ﬁve ﬁelds
at a magniﬁcation of ×200 and the average number of cells was calculated. CD8+,
CD4+, and FOXP3+ cells were counted from ﬁve ﬁelds at a magniﬁcation of ×400
and the average number of cells was calculated.
Flow cytometry. For murine samples, mice with tumors were euthanized by CO2
gas inhalation and spleens, femurs, tibias, and tumors were collected. Cells were
stained with the following antibodies for 30 min at 4 °C. Antibodies used are listed
in Supplementary Table 5. For IFNγ intracellular staining, a BD Cytoﬁx/Cytoperm
Fixation/Permeabilization Kit (BD Biosciences) was used. Non-viable cells were
stained with 7-amino-actinomycin D (AAD) solution or DAPI solution and gated
out. Matched isotype antibodies were used as controls. Data were acquired using a
MACS Quant (Miltenyi Biotec) or FACS Calibur (BD Biosciences), and analyzed
using MACS Quantify (Miltenyi Biotec) or Cell Quest Pro software (BD Bios-
ciences)14.
For human samples, ascites cells, ovarian tumor cells, and PBMCs were
collected from patients with ovarian cancer at the time of surgery. Cells were
stained with the following antibodies for 30 min at 4 °C. Antibodies used are listed
in Supplementary Table 5.
The puriﬁed mouse MDSC (CD11b+Gr1+) population was sorted from
subcutaneous tumor and ascites of mice inoculated with HM-1 cells using auto
magnetic-activated cell sorting (autoMACS Pro separator; Miltenyi Biotech)
according to the manufacturer’s protocol. The puriﬁed human MDSC (CD11b
+CD33+) population was sorted from patient ascites and ovarian tumor samples
using CD33 MicroBeads (Miltenyi Biotech) according to the manufacturer’s
protocol.
Chemotaxis assays. In vitro migration of murine MDSCs was evaluated in 24-well
plates with transwell polycarbonate-permeable supports (8.0 μm; Costar Corning,
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03966-7
10 NATURE COMMUNICATIONS |  (2018) 9:1685 | DOI: 10.1038/s41467-018-03966-7 | www.nature.com/naturecommunications
Cambridge, MA, USA). MDSCs (5 × 105; >80% purity) were plated in the upper
chambers of the inserts 30 min after incubation with a CXCR2 antagonist at each
concentration, and recombinant murine CXCL1, CXCL2, and CXCL5 (PeproTech)
were placed in the lower chamber at a concentration of 1, 10, or 100 ng/mL. After
incubation for 3 h, the number of MDSCs in the bottom compartment was counted
using Acubright counting beads (Life Technologies, Carlsbad, CA, USA)17.
To evaluate the migration of human MDSCs, MDSCs (1 × 105; >80% purity)
were plated in the upper chambers of the inserts 30 min after incubation with the
CXCR2 antagonist at each concentration, and recombinant human CXCL1,
CXCL2, and CXCL5 (PeproTech) were placed in the lower chamber at a
concentration of 1 or 10 ng/ml. After incubation for 6 h, the number of MDSCs in
the bottom compartment was counted36.
MDSC suppression assays. An aliquot of the Gr1+ sorted cells was stained with
an anti-CD11b antibody and analyzed by ﬂow cytometry to ensure purity (>80%)
of CD11b+Gr1+ cells. Carboxyﬂuorescein succinimidyl ester (CFSE; 10 μM) was
added to suspensions (1 × 107 cells/mL) of T cells separated from splenocytes of a
wild-type B6C3F1 mouse using a mouse Pan-T-cell isolation kit (Miltenyi Biotech).
Sorted MDSCs were added to CFSE-labeled T cells at different ratios, harvested in
96-well plates, and activated with Dynabeads Mouse T-activator CD3/28 (VER-
ITAS, Tokyo, Japan) for 72 h at 37 °C. T-cell proliferation was evaluated by ﬂow
cytometry14.
For human samples, CFSE was added to suspensions (1 × 107 cells/mL) of
T cells separated from PBMCs of healthy donors using a human Pan-T-cell
isolation kit (Miltenyi Biotech). Sorted MDSCs from human ovarian tumor
samples were added to CFSE-labeled T cells at different ratios, harvested in 96-well
plates, and activated with Dynabeads Human T-activator CD3/28 (VERITAS,
Tokyo, Japan) for 96 h at 37 °C.
Clinical specimens of HGSOC patients. Surgical specimens from patients with
HGSOC who underwent primary surgery at Kyoto University Hospital between
1996 and 2014 were collected. We selected 56 advanced cases (48 stage III cases and
8 stage IV cases) for which samples of the peritoneal dissemination could be
evaluated (Figs. 1, 3). The relevant clinical data were collected by retrospective
review of patient ﬁles. Patients receiving chemotherapy or radiation prior to sur-
gery were excluded.
Clinical samples for CXCL1 and CXCL2 measurements. Blood serum, surgical
specimens, and PBMCs from 26 patients (9 stage I cases, 2 stage II cases, 9 stage III
cases, and 6 stage IV cases) with primary ovarian cancer, who were treated at Kyoto
University Hospital between 2012 and 2013, and blood serum from 8 healthy
female donors were collected (Fig. 8). Patients receiving any prior treatment were
excluded. The relevant clinical data were collected by retrospective review of
patient ﬁles. To investigate Snail, CD33, CD8, CD4, and FOXP3 expression, we
selected 12 advanced cases (9 stage III cases and 3 stage IV cases) for which
samples of the peritoneal dissemination could be evaluated. Three out of all 6 stage
IV cases had not undergone primary surgery. PBMCs from 9 advanced cases
(6 stage III cases and 3 stage IV cases) were available (Supplementary Fig. 15).
ELISA, immunohistochemistry analysis, scoring, and ﬂow cytometry analysis were
performed as described previously. CXCL1 and CXCL2 were evaluated by receiver
operating characteristic curve analysis to deﬁne optimal cut-off levels for survival
data (Fig. 8e, f).
Clinical human patients’ ascites. Ascites cells from 13 patients with advanced
ovarian cancer (8 stage III cases and 5 stage IV cases), hospitalized for massive
cancerous ascites at Kyoto University Hospital between 2014 and 2015, were col-
lected (Supplementary Fig. 14). Flow cytometry analysis was performed as
described above.
Bioinformatics analyses. The TCGA HG-U133A dataset from the TCGA
Data Portal (http://cancergenome.nih.gov) was analyzed by single-sample Gene Set
Enrichment Analysis (ssGSEA) at the gene level, as previously described (Gene-
Pattern version 3.5.1; http://www.broadinstitute.org/cancer/software/genepattern).
Generic EMT scoring was used as previously described in ref. 3. For data analyses,
the ssGSEA scores were normalized from 0 to 1.
Microarray analysis. HM-1-control (n= 3), as well as HM-1-shSnail sh1 (n= 2)
and sh2 (n= 2), cells were harvested. Whole RNA was extracted using the RNeasy
Mini Kit (Qiagen), and was hybridized to an Affymetrix GeneChip® Mouse
Transcriptome Array 1.0 (Affymetrix) and analyzed using the Affymetrix®
Expression ConsoleTM and Affymetrix® Transcriptome Analysis Console by
GeneticLab (Hokkaido, Japan).
Statistics. All results were conﬁrmed using at least three independent in vitro
experiments or at least two independent in vivo experiments, and data from one
representative experiment are presented. Results are shown as the average ± stan-
dard error of the mean (SEM). Comparisons between two groups were performed
using Student’s t-tests. Group comparisons were performed using one-way
ANOVAs. The log-rank test was used for overall survival analysis, and multivariate
analysis was performed using Cox proportional hazards regression analysis. All
statistical analyses were performed using GraphPad Prism 6 and Rcmdr software
(http://www.rcommander.com/). The level of signiﬁcance was set as *P < 0.05, **P
< 0.01, ***P < 0.001, and ****P < 0.0001.
Study approval. All animal studies were approved by Kyoto University Animal
Research Committee. Human studies were approved by Kyoto University Graduate
School and Faculty of Medicine Ethics Committee. All human samples were
acquired after obtaining written informed consent from each patient. The patients
were identiﬁed by numbers.
Data availability. Microarray data have been deposited at Gene Expression
Omnibus with accession number GSE109688. All other data are freely available
from the corresponding author upon reasonable request.
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